Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease

• Autor(es): Majdi, Amine ; Aoudjehane, Lynda ; Ratziu, Vlad ; Islam, Tawhidul ; Afonso, Marta B ; Conti, Filomena ; Mestiri, Taïeb ; Lagouge, Marie ; Foufelle, Fabienne ; Ballenghien, Florine ; Ledent, Tatiana ; Moldes, Marthe ; Cadoret, Axelle ; Fouassier, Laura ; Delaunay, Jean-Louis ; Aït-Slimane, Tounsia ; Courtois, Gilles ; Fève, Bruno ; Scatton, Olivier ; Prip-Buus, Carina ; Rodrigues, Cecília M P ; Housset, Chantal ; Gautheron, Jérémie
• Data: 2020
• Identificador Persistente: https://hdl.handle.net/10316/95079
• Origem: Estudo Geral - Universidade de Coimbra
• Assunto(s): MLKL; NAFLD; NASH; Necroptosis; RIPK1; Steatosis
• Tipo de Documento: Artigo científico
• Idioma: Inglês

Descrição

In non-alcoholic fatty liver disease (NAFLD), hepatocytes can undergo necroptosis: a regulated form of necrotic cell death mediated by the receptor-interacting protein kinase (RIPK) 1. Herein, we assessed the potential for RIPK1 and its downstream effector mixed lineage kinase domain-like protein (MLKL) to act as therapeutic targets and markers of activity in NAFLD.